布地奈德混悬液雾化吸入对慢性阻塞性肺疾病急性期肺功能及炎性因子的影响

Effects of budesonide suspension aerosolized inhalation on pulmonary function and inflammatory factors after the treatment of chronic obstructive pulmonary disease in acute stage

目的探讨布地奈德混悬液雾化吸入辅助治疗慢性阻塞性肺疾病急性期的疗效及对炎性因子的影响。方法将100例COPD急性发作患者随机分为研究组(50例)和对照组(50例)。对照组采用抗感染、氧疗、解痉等对症治疗;研究组联合雾化吸入布地奈德混悬液治疗,对比两组7 d后肺功能、血清炎性因子水平与临床疗效。结果研究组FEV1%值及FEV1/FVC(%)值均高于对照组,研究组IL-4、TNF-α、IL-6水平均低于对照组,IL-10显著高于对照组(P<0.05)。研究组总有效率、临床控制率与对照组比较,差异有统计学意义。结论慢性阻塞性肺疾病急性期联合采用布地奈德雾化吸入方式可协同抑制炎性反应,调控细胞内炎性因子表达,有助于进一步提高慢性阻塞性肺疾病急性期的临床疗效。

Objective To investigate the treatment effects of aerosolized inhalation of budesonide suspension on the acute phase of chronic obstructive pulmonary disease and its effect on inflammatory factors. Methods A total of 100 patients with acute exacerbation of COPD were randomly divided into study group(n=50) and control group(n=50). The control group was treated with symptomatic treatment including anti-infection, oxygen therapy and antispasmodic. The study group was given combined treatment of aerosolized inhalation of budesonide suspension. The levels of pulmonary function and serum inflammatory factors and clinical efficacy were compared between the two groups after 7 days of treatment. Results The FEV1% and FEV1/FVC(%) in the study group were higher than those in the control group. The levels of IL-4, TNF-α and IL-6 in the study group were lower than those in the control group, and IL-10 in the study group was significantly higher than that in the control group(P<0.05). There were significant differences in total effective rate and clinical control rate between the study group and the control group. Conclusion The combination of budes onide aerosolized inhalation in the acute phase of chronic obstructive pulmonary disease can co-inhibit the inflammatory response and regulate the expression of intracellular inflammatory factors, which can help to further improve the clinical effect of chronic obstructive pulmonary disease in the acute period.